Published in Blood Weekly, September 30th, 1996
The anticoagulant drug, called innohep (tinzaparin) by Leo Laboratories Canada Ltd., belongs to a class of drugs called low molecular weight heparins that can significantly change the way patients with blood clots are managed.
"These new therapies are a real benefit for patients," said Dr. Graham Pineo, Calgary General Hospital. "The ability to receive treatment at home - instead of in a hospital bed hooked up to an intravenous unit - allows the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.